Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

休市中 05-17 16:00:00 EDT

16.35

-0.18

-1.09%

盘后16.35

+0.000.00%

16:08 EDT

最高17.25	最低16.21	成交量16.89万
今开16.50	昨收16.53	日振幅6.29%
总市值4.17亿	流通市值1.58亿	总股本2,553万
成交额281.00万	换手率1.75%	流通股本965.12万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":16.35,"timestamp":1715976000000,"preClose":16.53,"halted":0,"volume":168855,"hourTrading":{"tag":"盘后","latestPrice":16.35,"preClose":16.35,"latestTime":"16:08 EDT","volume":1081,"amount":17674.35,"timestamp":1715976536449},"delay":0,"floatShares":9651179,"shares":25534458,"eps":-7.123353,"marketStatus":"休市中","marketStatusCode":7,"change":-0.18,"latestTime":"05-17 16:00:00 EDT","open":16.5,"high":17.25,"low":16.21,"amount":2810042.189685,"amplitude":0.062916,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.123353,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"listingDate":1624593600000,"adjPreClose":16.53,"preHourTrading":{"tag":"盘前","latestPrice":16.926,"preClose":16.53,"latestTime":"08:05 EDT","volume":107,"amount":1775.843476,"timestamp":1715947528714},"postHourTrading":{"tag":"盘后","latestPrice":16.35,"preClose":16.35,"latestTime":"16:08 EDT","volume":1081,"amount":17674.35,"timestamp":1715976536449},"volumeRatio":0.9466282301934609},"requestUrl":"/m/hq/s/LENZ/","defaultTab":"news","newsList":[{"id":"2436333193","title":"Outlook Therapeutics, Inc.2024财年第一财季实现净利润-1.14亿美元，同比减少1614.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436333193","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436333193?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:20","pubTimestamp":1716135612,"startTime":"0","endTime":"0","summary":"3月31日，Outlook Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-1.14亿美元，同比减少1614.29%；其中营业收入为0.00美元，每股基本收益为-8.01美元。从资产负债表来看，Outlook Therapeutics, Inc.总负债1.93亿美元，其中短期债务44.75百万美元，资产负债比为30.59，流动比率为1.07。机构评级：截至2024年3月31日，当前有7家机构对Outlook Therapeutics, Inc.目标价做出预测，其中目标均价为38.86美元，其中最低目标价为25.00美元，最高目标价为53.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200020228b186af2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200020228b186af2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436198756","title":"Perspective Therapeutics, Inc.2024财年第一财季实现净利润-11.82百万美元，同比减少3085.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436198756","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436198756?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:17","pubTimestamp":1716135476,"startTime":"0","endTime":"0","summary":"3月31日，Perspective Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-11.82百万美元，同比减少3085.98%；其中营业收入为325000.00美元，同比减少84.22%，每股基本收益为-0.02美元。机构评级：截至2024年3月31日，当前有6家机构对Perspective Therapeutics, Inc.目标价做出预测，其中目标均价为2.22美元，其中最低目标价为1.70美元，最高目标价为3.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001800877abd0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001800877abd0f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436519804","title":"Biora Therapeutics, Inc.2024财年第一财季实现净利润-4.19百万美元，同比增加75.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436519804","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436519804?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:17","pubTimestamp":1716135452,"startTime":"0","endTime":"0","summary":"3月31日，Biora Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-4.19百万美元，同比增加75.97%；其中营业收入为542000.00美元，同比增加27000.00%，每股基本收益为-0.14美元。从资产负债表来看，Biora Therapeutics, Inc.总负债1.23亿美元，其中短期债务2.90百万美元，资产负债比为18.70，流动比率为0.28。机构评级：截至2024年3月31日，当前有2家机构对Biora Therapeutics, Inc.目标价做出预测，其中目标均价为10.30美元，其中最低目标价为5.60美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001734877abcd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001734877abcd8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436980921","title":"Adaptimmune Therapeutics Plc2024财年第一财季实现净利润-48.48百万美元，同比减少4717.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436980921","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436980921?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:16","pubTimestamp":1716135390,"startTime":"0","endTime":"0","summary":"3月31日，Adaptimmune Therapeutics Plc公布财报，公告显示公司2024财年第一财季净利润为-48.48百万美元，同比减少4717.14%；其中营业收入为5.67百万美元，同比减少88.19%，每股基本收益为-0.20美元。从资产负债表来看，Adaptimmune Therapeutics Plc总负债2.34亿美元，其中短期债务5.25百万美元，资产负债比为1.11，流动比率为0.03。机构评级：截至2024年3月31日，当前有7家机构对Adaptimmune Therapeutics Plc目标价做出预测，其中目标均价为2.86美元，其中最低目标价为1.00美元，最高目标价为5.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001641877abc57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001641877abc57&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436732198","title":"Plus Therapeutics, Inc.2024财年第一财季实现净利润-3.26百万美元，同比增加32.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436732198","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436732198?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:14","pubTimestamp":1716135270,"startTime":"0","endTime":"0","summary":"3月31日，Plus Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-3.26百万美元，同比增加32.22%；其中营业收入为1.68百万美元，同比增加232.02%，每股基本收益为-0.75美元。机构评级：截至2024年3月31日，当前有3家机构对Plus Therapeutics, Inc.目标价做出预测，其中目标均价为19.33美元，其中最低目标价为4.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001433877aba1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520001433877aba1c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436198110","title":"Mink Therapeutics, Inc.2024财年第一财季实现净利润-3.81百万美元，同比增加33.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436198110","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436198110?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:10","pubTimestamp":1716135037,"startTime":"0","endTime":"0","summary":"3月31日，Mink Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-3.81百万美元，同比增加33.04%；其中营业收入为0.00美元，每股基本收益为-0.11美元。从资产负债表来看，Mink Therapeutics, Inc.总负债27.19百万美元，其中短期债务0.00美元，资产负债比为0.26，流动比率为0.55。机构评级：截至2024年3月31日，当前有2家机构对Mink Therapeutics, Inc.目标价做出预测，其中目标均价为8.50美元，其中最低目标价为8.00美元，最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200010408b1862af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200010408b1862af&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436981531","title":"Fulcrum Therapeutics, Inc.2024财年第一财季实现净利润-26.87百万美元，同比减少8.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436981531","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436981531?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:06","pubTimestamp":1716134782,"startTime":"0","endTime":"0","summary":"3月31日，Fulcrum Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-26.87百万美元，同比减少8.43%；其中营业收入为0.00美元，每股基本收益为-0.43美元。机构评级：截至2024年3月31日，当前有8家机构对Fulcrum Therapeutics, Inc.目标价做出预测，其中目标均价为14.88美元，其中最低目标价为5.00美元，最高目标价为22.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200006298b185da1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405200006298b185da1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436538181","title":"Allogene Therapeutics, Inc.2024财年第一财季实现净利润-65.00百万美元，同比增加34.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436538181","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436538181?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:25","pubTimestamp":1716049528,"startTime":"0","endTime":"0","summary":"3月31日，Allogene Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-65.00百万美元，同比增加34.14%；其中营业收入为22000.00美元，同比减少57.69%，每股基本收益为-0.38美元。从资产负债表来看，Allogene Therapeutics, Inc.总负债1.25亿美元，其中短期债务6.93百万美元，资产负债比为4.69，流动比率为0.13。机构评级：截至2024年3月31日，当前有12家机构对Allogene Therapeutics, Inc.目标价做出预测，其中目标均价为11.59美元，其中最低目标价为4.50美元，最高目标价为35.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900253287781109&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900253287781109&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436181635","title":"Voyager Therapeutics, Inc.2024财年第一财季实现净利润-11.33百万美元，同比减少109.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436181635","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436181635?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:24","pubTimestamp":1716049487,"startTime":"0","endTime":"0","summary":"3月31日，Voyager Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-11.33百万美元，同比减少109.14%；其中营业收入为19.52百万美元，同比减少86.99%，每股基本收益为-0.20美元。机构评级：截至2024年3月31日，当前有9家机构对Voyager Therapeutics, Inc.目标价做出预测，其中目标均价为17.56美元，其中最低目标价为8.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190024538b15ef5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190024538b15ef5f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436181977","title":"Cara Therapeutics, Inc.2024财年第一财季实现净利润-30.70百万美元，同比减少15.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436181977","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436181977?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:23","pubTimestamp":1716049433,"startTime":"0","endTime":"0","summary":"3月31日，Cara Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-30.70百万美元，同比减少15.11%；其中营业收入为2.14百万美元，同比减少65.32%，每股基本收益为-0.56美元。从资产负债表来看，Cara Therapeutics, Inc.总负债60.30百万美元，其中短期债务220000.00美元，资产负债比为1.50，流动比率为5.38。机构评级：截至2024年3月31日，当前有5家机构对Cara Therapeutics, Inc.目标价做出预测，其中目标均价为5.12美元，其中最低目标价为1.00美元，最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900240187781074&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900240187781074&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436437181","title":"Iterum Therapeutics Plc2024财年第一财季实现净利润-7.10百万美元，同比增加28.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436437181","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436437181?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:23","pubTimestamp":1716049406,"startTime":"0","endTime":"0","summary":"3月31日，Iterum Therapeutics Plc公布财报，公告显示公司2024财年第一财季净利润为-7.10百万美元，同比增加28.21%；其中营业收入为0.00美元，每股基本收益为-0.46美元。从资产负债表来看，Iterum Therapeutics Plc总负债25.78百万美元，其中短期债务12.57百万美元，资产负债比为0.77，流动比率为1.08。机构评级：截至2024年3月31日，当前有2家机构对Iterum Therapeutics Plc目标价做出预测，其中目标均价为6.50美元，其中最低目标价为6.00美元，最高目标价为7.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190023368778104e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190023368778104e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436818120","title":"Soleno Therapeutics, Inc.2024财年第一财季实现净利润-21.40百万美元，同比减少155.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436818120","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436818120?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:20","pubTimestamp":1716049252,"startTime":"0","endTime":"0","summary":"3月31日，Soleno Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-21.40百万美元，同比减少155.98%；其中营业收入为0.00美元，每股基本收益为-0.59美元。机构评级：截至2024年3月31日，当前有7家机构对Soleno Therapeutics, Inc.目标价做出预测，其中目标均价为67.29美元，其中最低目标价为59.00美元，最高目标价为93.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190021048b15edcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190021048b15edcb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436181641","title":"Virios Therapeutics, Inc.2024财年第一财季实现净利润-1.29百万美元，同比增加15.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436181641","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436181641?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:18","pubTimestamp":1716049132,"startTime":"0","endTime":"0","summary":"3月31日，Virios Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-1.29百万美元，同比增加15.13%；其中营业收入为0.00美元，每股基本收益为-0.07美元。从资产负债表来看，Virios Therapeutics, Inc.总负债570083.00美元，其中短期债务0.00美元，资产负债比为0.01，流动比率为0.01。机构评级：截至2024年3月31日，当前有1家机构对Virios Therapeutics, Inc.目标价做出预测，其中目标均价为0.40美元，其中最低目标价为0.40美元，最高目标价为0.40美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900185887780e4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900185887780e4d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436358181","title":"Revance Therapeutics, Inc.2024财年第一财季实现净利润-49.53百万美元，同比增加17.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436358181","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436358181?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:18","pubTimestamp":1716049087,"startTime":"0","endTime":"0","summary":"3月31日，Revance Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-49.53百万美元，同比增加17.16%；其中营业收入为51.94百万美元，同比增加5.29%，每股基本收益为-0.58美元。从资产负债表来看，Revance Therapeutics, Inc.总负债6.07亿美元，其中短期债务12.13百万美元，资产负债比为0.84，流动比率为0.06。机构评级：截至2024年3月31日，当前有11家机构对Revance Therapeutics, Inc.目标价做出预测，其中目标均价为12.82美元，其中最低目标价为6.00美元，最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190018198b15ecb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190018198b15ecb6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436811321","title":"Mineralys Therapeutics, Inc.2024财年第一财季实现净利润-31.51百万美元，同比减少149.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436811321","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436811321?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:17","pubTimestamp":1716049035,"startTime":"0","endTime":"0","summary":"3月31日，Mineralys Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-31.51百万美元，同比减少149.88%；其中营业收入为0.00美元，每股基本收益为-0.70美元。机构评级：截至2024年3月31日，当前有6家机构对Mineralys Therapeutics, Inc.目标价做出预测，其中目标均价为33.50美元，其中最低目标价为26.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190017288b15ec41&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436816631","title":"Oncternal Therapeutics, Inc.2024财年第一财季实现净利润-8.39百万美元，同比增加26.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436816631","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436816631?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:16","pubTimestamp":1716048992,"startTime":"0","endTime":"0","summary":"3月31日，Oncternal Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-8.39百万美元，同比增加26.98%；其中营业收入为569000.00美元，同比增加180.30%，每股基本收益为-2.83美元。从资产负债表来看，Oncternal Therapeutics, Inc.总负债6.22百万美元，其中短期债务179000.00美元，资产负债比为4.69，流动比率为4.66。机构评级：截至2024年3月31日，当前有3家机构对Oncternal Therapeutics, Inc.目标价做出预测，其中目标均价为27.67美元，其中最低目标价为19.00美元，最高目标价为39.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190016368b15eb93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190016368b15eb93&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436189741","title":"Akebia Therapeutics, Inc.2024财年第一财季实现净利润-17.99百万美元，同比增加31.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436189741","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436189741?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:16","pubTimestamp":1716048973,"startTime":"0","endTime":"0","summary":"3月31日，Akebia Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-17.99百万美元，同比增加31.39%；其中营业收入为32.61百万美元，同比减少18.74%，每股基本收益为-0.09美元。机构评级：截至2024年3月31日，当前有3家机构对Akebia Therapeutics, Inc.目标价做出预测，其中目标均价为5.00美元，其中最低目标价为4.00美元，最高目标价为6.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900162387780caa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051900162387780caa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436684181","title":"Sangamo Therapeutics, Inc.2024财年第一财季实现净利润-49.09百万美元，同比减少332.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436684181","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436684181?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:14","pubTimestamp":1716048840,"startTime":"0","endTime":"0","summary":"3月31日，Sangamo Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-49.09百万美元，同比减少332.32%；其中营业收入为481000.00美元，同比减少99.70%，每股基本收益为-0.27美元。机构评级：截至2024年3月31日，当前有6家机构对Sangamo Therapeutics, Inc.目标价做出预测，其中目标均价为3.50美元，其中最低目标价为1.00美元，最高目标价为8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190014058b15e995&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190014058b15e995&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436189274","title":"Lisata Therapeutics, Inc.2024财年第一财季实现净利润-5.40百万美元，同比增加12.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436189274","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436189274?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:09","pubTimestamp":1716048540,"startTime":"0","endTime":"0","summary":"3月31日，Lisata Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-5.40百万美元，同比增加12.76%；其中营业收入为0.00美元，每股基本收益为-0.65美元。从资产负债表来看，Lisata Therapeutics, Inc.总负债5.50百万美元，其中短期债务172000.00美元，资产负债比为8.78，流动比率为8.93。机构评级：截至2024年3月31日，当前有2家机构对Lisata Therapeutics, Inc.目标价做出预测，其中目标均价为14.50美元，其中最低目标价为14.00美元，最高目标价为15.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240519000913877804df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240519000913877804df&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436018143","title":"Lineage Cell Therapeutics, Inc.2024财年第一财季实现净利润-6.54百万美元，同比减少49.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436018143","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436018143?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:06","pubTimestamp":1716048362,"startTime":"0","endTime":"0","summary":"3月31日，Lineage Cell Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-6.54百万美元，同比减少49.66%；其中营业收入为1.44百万美元，同比减少39.75%，每股基本收益为-0.04美元。从资产负债表来看，Lineage Cell Therapeutics, Inc.总负债37.49百万美元，其中短期债务1.10百万美元，资产负债比为0.03，流动比率为2.71。机构评级：截至2024年3月31日，当前有5家机构对Lineage Cell Therapeutics, Inc.目标价做出预测，其中目标均价为5.20美元，其中最低目标价为4.00美元，最高目标价为7.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190006048b15e2f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190006048b15e2f3&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.0394},{"period":"1month","weight":-0.0763},{"period":"3month","weight":-0.2317},{"period":"6month","weight":0.0025},{"period":"1year","weight":-0.1833},{"period":"ytd","weight":-0.1085}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.于2017年6月1日加拿大安大略省注册成立，并于2019年10月在特拉华州重新注册。他们是一家临床阶段的下一代基因编辑公司，利用高效靶向基因整合开发新型疗法有可能治愈范围广泛的严重和危及生命的疾病。他们正在开创一种精确的基因编辑方法，以实现医学上最难以实现的目标之一：精确“找到并替换”基因组中的任何基因。他们的下一代基因编辑平台使他们能够精确地纠正突变，用正常基因替换整个致病基因，或将新基因插入预定的安全位置。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.164965},{"month":6,"riseRate":0.5,"avgChangeRate":0.042853},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.062127},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.052314},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.028796},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.037137},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.124883},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}